Inflammation‐based prognostic scoring system for predicting the prognosis of advanced small cell lung cancer patients receiving anlotinib monotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Laboratory Analysis"
DOI: 10.1002/jcla.24772
Abstract: According to the randomized multicenter phase II trial (ALTER1202), anlotinib has been approved as a third‐line therapy for advanced small‐cell lung cancer (SCLC). Some studies showed the predictive function of inflammatory markers, including neutrophil‐to‐lymphocyte ratio… read more here.
Keywords: lung cancer; advanced small; receiving anlotinib; small cell ... See more keywords
Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.812555
Abstract: Background: Anlotinib is a novel anti-angiogenesis drug. In non-small cell lung cancer (NSCLC), high body mass index (BMI) was not associated with worse survival in patients treated with bevacizumab compared with those with normal or… read more here.
Keywords: patients receiving; obesity; anlotinib advanced; receiving anlotinib ... See more keywords